ARK Genomic Revolution ETF (ARKG)
- Fund company
- ARK ETF Trust
- Fund net assets
- $1.6B
- Equity lines
- 32
- Holdings as of
- 31 July 2026
- Source
- N-PORT report, SEC →
Weighted score of the companies held
59% of the fund (by weight) is scored by Scorvest. 0% of the fund is invested in companies scored 75 or more, 54% in companies below 40.
32
- Profitability
- 8
- Balance sheet
- 58
- Cash generation
- 22
- Stability
- 25
- Growth
- 67
Fund split by score
- Scored 75+ 0%
- Scored 40–74 5%
- Scored below 40 54%
- Not scored yet 41%
Sectors
Countries
Top holdings
| Company | Weight | Score | |
|---|---|---|---|
| 10x Genomics, Inc. | 9.39% | 34 | |
| Twist Bioscience Corp | 7.73% | 30 | |
| Tempus AI, Inc. | 6.56% | 30 | |
| CRISPR Therapeutics AG | 6.29% | 36 | |
| Personalis, Inc. | 5.47% | 15 | |
| Absci Corp | 5.14% | 16 | |
| Guardant Health, Inc. | 4.74% | 26 | |
| ILLUMINA, INC. | 4.74% | 68 | |
| ELI LILLY & COMPANY | 4.68% | pending | |
| CareDx, Inc. | 4.30% | 32 | |
The next 22 holdings are visible from the Essential plan. Try free for 7 days → | |||
Computed from the equity lines reported by the fund. Weights are those of the N-PORT report at the date shown. General information, not investment advice.